CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 25 enrolled
Drug / intervention
abataceptdrug
Likely dose
abatacept 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01299961
NCT01299961Phase 3Completed
CompareCT.gov

Musculoskeletal Ultrasound as a Marker of Therapeutic Response to Abatacept in Rheumatoid Arthritis

University of California, Los Angeles·interventional·Posted Feb 21, 2011·Updated Jun 10, 2015

In Brief

A Phase 3 clinical trial evaluating abatacept for Rheumatoid Arthritis. Completed, enrolled 25 participants across 1 site.

Detailed Summary

Rheumatoid arthritis (RA) is a chronic inflammatory disease (a long-lasting disease causing pain and swelling) associated with significant health problems. It is a difficult disease to manage as the disease is often unpredictable. RA causes inflammation (swelling) of the joints that can cause joint damage, deformity, and progressive disability and impairment. It is estimated that 1% of the world's population suffers from this disease. The purpose of this research study is to determine if a change in inflammation seen on the ultrasound is a good indicator of how subjects' rheumatoid arthritis is responding to treatment of subcutaneous abatacept at 3 weeks, 3 months, 6 months, and 12 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 21, 2011
Enrollment StartMar 1, 2011
Primary CompletionFeb 1, 2013
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 15.4 years ago

Interventions

abataceptdrug

125 mg once a week up to 12 months.